{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:51:03Z","timestamp":1762102263199,"version":"3.37.3"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T00:00:00Z","timestamp":1535932800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00280-018-3679-4","type":"journal-article","created":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T04:26:08Z","timestamp":1535948768000},"page":"865-876","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM\u2122 system in a quaternary oncology centre"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9188-3376","authenticated-orcid":false,"given":"Michael","family":"Moloney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Faulkner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Link","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Rischin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette M.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Zalcberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Jefford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Michael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,3]]},"reference":[{"issue":"11","key":"3679_CR1","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1200\/JCO.1985.3.11.1486","volume":"3","author":"KS Dasmahapatra","year":"1985","unstructured":"Dasmahapatra KS, Citrin P, Hill G, Yee R, Mohit-Tabatabai M, Rush B Jr (1985) A prospective evaluation of 5-fluorouracil plus cisplatin in advanced squamous-cell cancer of the head and neck. J Clin Oncol 3(11):1486\u20131489","journal-title":"J Clin Oncol"},{"issue":"12","key":"3679_CR2","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1517\/14656566.4.12.2151","volume":"4","author":"DJ Adelstein","year":"2003","unstructured":"Adelstein DJ (2003) Systemic chemotherapy for squamous cell head and neck cancer. Expert Opin Pharmacother 4(12):2151\u20132163","journal-title":"Expert Opin Pharmacother"},{"issue":"17","key":"3679_CR3","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1200\/JCO.2005.05.3629","volume":"24","author":"DJ Adelstein","year":"2006","unstructured":"Adelstein DJ, LeBlanc M (2006) Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer? J Clin Oncol 24(17):2624\u20132628","journal-title":"J Clin Oncol"},{"issue":"7","key":"3679_CR4","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/hed.20381","volume":"28","author":"D Goldenberg","year":"2006","unstructured":"Goldenberg D, Sciubba J, Koch WM (2006) Cystic metastasis from head and neck squamous cell cancer: a distinct disease variant? Head Neck 28(7):633\u2013638","journal-title":"Head Neck"},{"issue":"11","key":"3679_CR5","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359(11):1116\u20131127","journal-title":"N Engl J Med"},{"issue":"24","key":"3679_CR6","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1093\/jnci\/91.24.2081","volume":"91","author":"G Calais","year":"1999","unstructured":"Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P et al (1999) Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91(24):2081\u20132086","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"3679_CR7","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1200\/JCO.1991.9.11.1967","volume":"9","author":"MA Poon","year":"1991","unstructured":"Poon MA, O\u2019Connell MJ, Wieand HS, Krook JE, Gerstner JB, Tschetter LK et al (1991) Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9(11):1967\u20131972","journal-title":"J Clin Oncol"},{"issue":"16","key":"3679_CR8","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"AD Gramont de","year":"2000","unstructured":"de Gramont AD, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938\u20132947","journal-title":"J Clin Oncol"},{"issue":"9209","key":"3679_CR9","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","volume":"355","author":"J Douillard","year":"2000","unstructured":"Douillard J, Cunningham D, Roth A, Navarro M, James R, Karasek P et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355(9209):1041\u20131047","journal-title":"Lancet"},{"issue":"24","key":"3679_CR10","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/jnci\/94.24.1883","volume":"94","author":"SD Baker","year":"2002","unstructured":"Baker SD, Verweij J, Rowinsky EK, Donehower RC, Schellens JH, Grochow LB et al (2002) Role of body surface area in dosing of investigational anticancer agents in adults, 1991\u20132001. J Natl Cancer Inst 94(24):1883\u20131888","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"3679_CR11","first-page":"2039","volume":"4","author":"R Fety","year":"1998","unstructured":"Fety R, Rolland F, Barberi-Heyob M, Hardouin A, Campion L, Conroy T et al (1998) Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res 4(9):2039\u20132045","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3679_CR12","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nrc1629","volume":"5","author":"SD Undevia","year":"2005","unstructured":"Undevia SD, Gomez-Abuin G, Ratain MJ (2005) Pharmacokinetic variability of anticancer agents. Nat Rev Cancer 5(6):447\u2013458","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"3679_CR13","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1200\/JCO.1996.14.9.2590","volume":"14","author":"H Gurney","year":"1996","unstructured":"Gurney H (1996) Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 14(9):2590\u20132611","journal-title":"J Clin Oncol"},{"issue":"13","key":"3679_CR14","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S0959-8049(02)00151-X","volume":"38","author":"A Felici","year":"2002","unstructured":"Felici A, Verweij J, Sparreboom A (2002) Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer 38(13):1677\u20131684","journal-title":"Eur J Cancer"},{"issue":"11","key":"3679_CR15","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1200\/JCO.1998.16.11.3537","volume":"16","author":"E Levy","year":"1998","unstructured":"Meta-Analysis Group In C, Levy E, Piedbois P, Buyse M, Pignon JP, Rougier P et al (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 16(11):3537\u20133541","journal-title":"J Clin Oncol"},{"issue":"1","key":"3679_CR16","first-page":"197","volume":"50","author":"BE Harris","year":"1990","unstructured":"Harris BE, Song R, Soong SJ, Diasio RB (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50(1):197\u2013201","journal-title":"Cancer Res"},{"issue":"3","key":"3679_CR17","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/bcp.13007","volume":"82","author":"BA Jacobs","year":"2016","unstructured":"Jacobs BA, Deenen MJ, Pluim D, van Hasselt JG, Krahenbuhl MD, van Geel RM et al (2016) Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers. Br J Clin Pharmacol 82(3):706\u2013716","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"3679_CR18","doi-asserted-by":"publisher","first-page":"dju298","DOI":"10.1093\/jnci\/dju298","volume":"106","author":"AM Lee","year":"2014","unstructured":"Lee AM, Shi Q, Pavey E et al (2014) DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst 106(12):dju298. \n                    https:\/\/doi.org\/10.1093\/jnci\/dju298","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"3679_CR19","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","volume":"16","author":"D Meulendijks","year":"2015","unstructured":"Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U et al (2015) Clinical relevance of DPYD variants c.1679T\u2009>\u2009G, c.1236G\u2009>\u2009A\/HapB3, and c.1601G\u2009>\u2009A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 16(16):1639\u20131650","journal-title":"Lancet Oncol"},{"issue":"3","key":"3679_CR20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/1097-0142(19910801)68:3<499::AID-CNCR2820680309>3.0.CO;2-F","volume":"68","author":"BE Harris","year":"1991","unstructured":"Harris BE, Carpenter JT, Diasio RB (1991) Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer 68(3):499\u2013501","journal-title":"Cancer"},{"issue":"1","key":"3679_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1172\/JCI113308","volume":"81","author":"RB Diasio","year":"1988","unstructured":"Diasio RB, Beavers TL, Carpenter JT (1988) Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 81(1):47\u201351","journal-title":"J Clin Invest"},{"issue":"3","key":"3679_CR22","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1200\/JCO.2015.63.1325","volume":"34","author":"MJ Deenen","year":"2016","unstructured":"Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H et al (2016) Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol 34(3):227\u2013234","journal-title":"J Clin Oncol"},{"issue":"7","key":"3679_CR23","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ejca.2003.12.004","volume":"40","author":"AB Kuilenburg van","year":"2004","unstructured":"van Kuilenburg AB (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40(7):939\u2013950","journal-title":"Eur J Cancer"},{"issue":"12","key":"3679_CR24","first-page":"4705","volume":"6","author":"AB Kuilenburg van","year":"2000","unstructured":"van Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, De Abreu RA et al (2000) Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 6(12):4705\u20134712","journal-title":"Clin Cancer Res"},{"issue":"9","key":"3679_CR25","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1023\/A:1012294617392","volume":"12","author":"A Paolo Di","year":"2001","unstructured":"Di Paolo A, Danesi R, Falcone A, Cionini L, Vannozzi F, Masi G et al (2001) Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann Oncol 12(9):1301\u20131306","journal-title":"Ann Oncol"},{"issue":"3","key":"3679_CR26","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/ijc.10599","volume":"101","author":"AB Kuilenburg Van","year":"2002","unstructured":"Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH (2002) Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14\u2009+\u20091g\u2009>\u2009a mutation. Int J Cancer 101(3):253\u2013258","journal-title":"Int J Cancer"},{"issue":"22","key":"3679_CR27","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1093\/jnci\/djp328","volume":"101","author":"MW Saif","year":"2009","unstructured":"Saif MW, Choma A, Salamone SJ, Chu E (2009) Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst 101(22):1543\u20131552","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"3679_CR28","first-page":"2930","volume":"42","author":"JL-S Au","year":"1982","unstructured":"Au JL-S, Rustum YM, Ledesma E, Mittelman A, Creaven PJ (1982) Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. Cancer Res 42(7):2930\u20132937","journal-title":"Cancer Res"},{"issue":"23","key":"3679_CR29","first-page":"6956","volume":"48","author":"CJ Groeningen van","year":"1988","unstructured":"van Groeningen CJ, Pinedo HM, Heddes J, Kok RM, de Jong AP, Wattel E et al (1988) Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res 48(23):6956\u20136961","journal-title":"Cancer Res"},{"issue":"5","key":"3679_CR30","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/BF02897292","volume":"26","author":"T Yoshida","year":"1990","unstructured":"Yoshida T, Araki E, Iigo M, Fujii T, Yoshino M, Shimada Y et al (1990) Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer. Cancer Chemother Pharmacol 26(5):352\u2013354","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"3679_CR31","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1200\/JCO.1991.9.11.2027","volume":"9","author":"DL Trump","year":"1991","unstructured":"Trump DL, Egorin MJ, Forrest A, Willson J, Remick S, Tutsch KD (1991) Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-h continuous infusion with and without dipyridamole. J Clin Oncol 9(11):2027\u20132035","journal-title":"J Clin Oncol"},{"issue":"4","key":"3679_CR32","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.1998.16.4.1470","volume":"16","author":"E Gamelin","year":"1998","unstructured":"Gamelin E, Boisdron-Celle M, Delva R, Regimbeau C, Cailleux P, Alleaume C et al (1998) Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol 16(4):1470\u20131478","journal-title":"J Clin Oncol"},{"issue":"3B","key":"3679_CR33","first-page":"2229","volume":"19","author":"M Ychou","year":"1998","unstructured":"Ychou M, Duffour J, Pinguet F, Kramar A, Joulia J, Topart D et al (1998) Individual 5FU-dose adaptation schedule using bimonthly pharmacokinetically modulated LV5FU2 regimen: a feasibility study in patients with advanced colorectal cancer. Anticancer Res 19(3B):2229\u20132235","journal-title":"Anticancer Res"},{"issue":"4","key":"3679_CR34","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s00280-003-0658-0","volume":"52","author":"M Ychou","year":"2003","unstructured":"Ychou M, Duffour J, Kramar A, Debrigode C, Gourgou S, Bressolle F et al (2003) Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. Cancer Chemother Pharmacol 52(4):282\u2013290","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"3679_CR35","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/bjc.1978.278","volume":"38","author":"B Hillcoat","year":"1978","unstructured":"Hillcoat B, McCulloch P, Figueredo A, Ehsan MH, Rosenfeld J (1978) Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion. Br J Cancer 38(6):719","journal-title":"Br J Cancer"},{"issue":"9","key":"3679_CR36","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1158\/1078-0432.CCR-07-1529","volume":"14","author":"A Paolo Di","year":"2008","unstructured":"Di Paolo A, Lencioni M, Amatori F, Di Donato S, Bocci G, Orlandini C et al (2008) 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. Clin Cancer Res 14(9):2749\u20132755","journal-title":"Clin Cancer Res"},{"issue":"13","key":"3679_CR37","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1200\/JCO.2007.13.3934","volume":"26","author":"E Gamelin","year":"2008","unstructured":"Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D et al (2008) Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 26(13):2099\u20132105","journal-title":"J Clin Oncol"},{"issue":"4","key":"3679_CR38","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.clcc.2012.05.004","volume":"11","author":"O Capitain","year":"2012","unstructured":"Capitain O, Asevoaia A, Boisdron-Celle M, Poirier A-L, Morel A, Gamelin E (2012) Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. Clin Colorectal Cancer 11(4):263\u2013267","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"3679_CR39","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.clcc.2013.11.001","volume":"13","author":"CLB Kline","year":"2014","unstructured":"Kline CLB, Schiccitano A, Zhu J, Beachler C, Sheikh H, Harvey HA et al (2014) Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early-or late-stage colorectal cancer patients treated with infusional 5-Fluorouracil-based chemotherapy regimens. Clin Colorectal Cancer 13(2):119\u2013126","journal-title":"Clin Colorectal Cancer"},{"issue":"3","key":"3679_CR40","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.clcc.2011.03.015","volume":"10","author":"J Saam","year":"2011","unstructured":"Saam J, Critchfield GC, Hamilton SA, Roa BB, Wenstrup RJ, Kaldate RR (2011) Body surface area-based dosing of 5-Fluoruracil results in extensive interindividual variability in 5-Fluorouracil exposure in colorectal cancer patients on FOLFOX regimens. Clin Colorectal Cancer 10(3):203\u2013206","journal-title":"Clin Colorectal Cancer"},{"issue":"6","key":"3679_CR41","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s00280-016-3184-6","volume":"78","author":"T Denda","year":"2016","unstructured":"Denda T, Kanda M, Morita Y, Kim HM, Kashiwada T, Matsuda C et al (2016) Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial. Cancer Chemother Pharmacol 78(6):1253\u20131261","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"3679_CR42","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.clcc.2016.04.001","volume":"15","author":"M Wilhelm","year":"2016","unstructured":"Wilhelm M, Mueller L, Miller MC, Link K, Holdenrieder S, Bertsch T et al (2016) Prospective, multicenter study of 5-Fluorouracil therapeutic drug monitoring in metastatic colorectal cancer treated in routine clinical practice. Clin Colorectal Cancer 15(4):381\u2013388","journal-title":"Clin Colorectal Cancer"},{"issue":"3 suppl","key":"3679_CR43","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1200\/jco.2015.33.3_suppl.563","volume":"33","author":"G Goel","year":"2015","unstructured":"Goel G, Sehgal R, Meisner DJ, Sun M, Pasricha G, Chu E et al (2015) Therapeutic drug monitoring of 5-fluorouracil (5-FU) in the treatment of patients with colorectal cancer (CRC). J Clin Oncol 33(3 suppl):563","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"3679_CR44","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1200\/jco.2014.32.15_suppl.3574","volume":"32","author":"FS Braiteh","year":"2014","unstructured":"Braiteh FS, Salamone SJ, Li Y, Courtney JB, Duda M, Diamond S et al (2014) Pharmacokinetic (PK)-guided optimization of 5-fluorouracil (5FU) exposure in colorectal cancer (CRC) patients: US-based clinical practices experience. J Clin Oncol 32(15 suppl):3574","journal-title":"J Clin Oncol"},{"issue":"9","key":"3679_CR45","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1634\/theoncologist.2014-0132","volume":"19","author":"JN Patel","year":"2014","unstructured":"Patel JN, O\u2019Neil BH, Deal AM, Ibrahim JG, Sherrill GB, Olajide OA et al (2014) A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy. Oncologist 19(9):959\u2013965","journal-title":"Oncologist"},{"issue":"3","key":"3679_CR46","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10637-008-9182-8","volume":"27","author":"M Michael","year":"2009","unstructured":"Michael M, Gibbs P, Smith R, Godwood A, Oliver S, Tebbutt N (2009) Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer. Investig New Drugs 27(3):253\u2013261","journal-title":"Investig New Drugs"},{"issue":"2","key":"3679_CR47","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00280-012-2009-5","volume":"71","author":"M Michael","year":"2013","unstructured":"Michael M, Zalcberg J, Gibbs P, Lipton L, Gouillou M, Jefford M et al (2013) A phase I trial of imatinib in combination with mFOLFOX6\u2013bevacizumab in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 71(2):321\u2013330","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"3679_CR48","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/BF00255288","volume":"16","author":"A Thyss","year":"1986","unstructured":"Thyss A, Milano G, Ren\u00e9e N, Vallicioni J, Schneider M, Demard F (1986) Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother Pharmacol 16(1):64\u201366","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"3679_CR49","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/bjc.1989.59","volume":"59","author":"J Santini","year":"1989","unstructured":"Santini J, Milano G, Thyss A, Renee N, Viens P, Ayela P et al (1989) 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 59(2):287","journal-title":"Br J Cancer"},{"issue":"6","key":"3679_CR50","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1023\/A:1008334313918","volume":"10","author":"D Zahnd","year":"1999","unstructured":"Zahnd D, Aebi S, Rusterholz S, Fey M, Borner M (1999) A randomized crossover trial assessing patient preference for two different types of portable infusion-pump devices. Ann Oncol 10(6):727\u2013729","journal-title":"Ann Oncol"},{"issue":"1","key":"3679_CR51","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/00115550-200301000-00004","volume":"28","author":"BM Ilfeld","year":"2003","unstructured":"Ilfeld BM, Morey TE, Enneking FK (2003) Delivery rate accuracy of portable, bolus-capable infusion pumps used for patient-controlled continuous regional analgesia. Reg Anesth Pain Med 28(1):17\u201323","journal-title":"Reg Anesth Pain Med"},{"issue":"4","key":"3679_CR52","first-page":"533","volume":"51","author":"T Kaye","year":"1994","unstructured":"Kaye T (1994) Prolonged infusion times with disponible elastomeric, infusion devices. AJHP Am J Hosp Pharm 51(4):533\u2013534","journal-title":"AJHP Am J Hosp Pharm"},{"issue":"5","key":"3679_CR53","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/ajhp\/52.5.500","volume":"52","author":"DF Veal","year":"1995","unstructured":"Veal DF, Altman CE, McKinnon BT, Fillingim O (1995) Evaluation of flow rates for six disposable infusion devices. Am J Health Syst Pharm 52(5):500\u2013504","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"3679_CR54","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1177\/1078155207078349","volume":"13","author":"M Ackermann","year":"2007","unstructured":"Ackermann M, Maier S, Ing H, Bonnabry P (2007) Evaluation of the design and reliability of three elastomeric and one mechanical infusers. J Oncol Pharm Practice 13(2):77\u201384","journal-title":"J Oncol Pharm Practice"},{"issue":"1","key":"3679_CR55","doi-asserted-by":"publisher","first-page":"119","DOI":"10.5313\/wja.v3.i1.119","volume":"3","author":"MBT LeReiger","year":"2014","unstructured":"LeReiger MBT, Martin D, Bessesworth J, Tobias JD (2014) Comparison of flow rate accuracy and consistency between the on-Q, baxter, and ambu pain devices. World J Anesthesiol 3(1):119\u2013123","journal-title":"World J Anesthesiol"},{"issue":"3","key":"3679_CR56","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/(SICI)1097-0142(19960201)77:3<441::AID-CNCR4>3.0.CO;2-N","volume":"77","author":"EC Gamelin","year":"1996","unstructured":"Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, Maillart PJ, Goudier M, Burtin PC et al (1996) Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 77(3):441\u2013451","journal-title":"Cancer"},{"issue":"4","key":"3679_CR57","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2165\/00003088-198916040-00002","volume":"16","author":"RB Diasio","year":"1989","unstructured":"Diasio RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16(4):215\u2013237","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"3679_CR58","first-page":"83","volume":"49","author":"M Blaschke","year":"2011","unstructured":"Blaschke M, Cameron S, Emami K, Blumberg J, Wegner U, Nischwitz M et al (2011) Measurement of 5-FU plasma levels in patients with advanced cancer: correct approach to practical procedures is essential. Int J Clin Pharmacol Ther 49(1):83","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"3679_CR59","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/BF03257473","volume":"51","author":"AB Kuilenburg van","year":"2012","unstructured":"van Kuilenburg AB, Hausler P, Schalhorn A, Tanck MW, Proost JH, Terborg C et al (2012) Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905\u2009+\u20091G\u2009>\u2009A mutation in DPYD by means of a Bayesian limited sampling strategy. Clin Pharmacokinet 51(3):163\u2013174","journal-title":"Clin Pharmacokinet"},{"issue":"91","key":"3679_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19910","volume":"19","author":"K Freeman","year":"2015","unstructured":"Freeman K, Connock M, Cummins E, Gurung T, Taylor-Phillips S, Court R et al (2015) Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion. Health Technol Assess (Winch Engl) 19(91):1","journal-title":"Health Technol Assess (Winch Engl)"},{"key":"3679_CR61","unstructured":"ClinicalTrials.gov Study comparing optimized 5-FU dosing and standard dosing in metastatic colorectal cancer patients treated with FOLFOX6 (PROFUSE)"},{"issue":"9863","key":"3679_CR62","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):303\u2013312","journal-title":"Lancet"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3679-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3679-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3679-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T19:12:55Z","timestamp":1567451575000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3679-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,3]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["3679"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3679-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2018,9,3]]},"assertion":[{"value":"8 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institution and the national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}